Media & Technology
INFRASTRUCTURE Play Social Detention (OTCMKTS: SODE) Gaining Mileage
Social Detention. Inc. (OTCMKTS: SODE) and its core business have been around for years growing organically by bidding on California government jobs for prisons, parks, and roadways etc. The company, which works closely with the Department of Transportation, had been quietly trading around the .02-.03 range in the early part of 2020 until it made an electrifying press release that jolted the OTC world in mid-March of this year as it soared to $.92.
The shocking news revealed their planned acquisition of Danliv Inc, a business licensed to conduct EV, Hydrogen and Green Projects, such as charging stations. The terms of the acquisition were outlined, via a stock purchase agreement that was executed on 3-11-20 and the stock price of SODE opened at .04 and hit a mid-day high of $0.92 while trading 36.8 million shares on the day. The news certainly turned a few heads.
Social Detention Inc. (OTCMKTS: SODE) shares were soon forgotten as cryptocurrency and oil and gas plays caught the attention of OTC traders. The company has not followed up with news since that release nearly 5 months ago and its share price slowly slid back to the .06 range (almost a 95% pullback from the high of 0.92).
With President Biden’s latest $1.2 Trillion Infrastructure Bill passing in the Senate and heading next door to the House of Representatives, investors have been scurrying the market screeners looking for solid infrastructure plays. If that wasn’t reason enough to do some ticker searching, $3.5 trillion is also on the menu for more in depth infrastructure needs. Based on the simple fact that the government will have an “open wallet” for spending, Social Detention once again has started drawing some attention as a potential candidate to land future contracts which is why the press release in March deserves a second look.
The Danliv Inc. Deal
This was a stock exchange of restricted shares. The missing ingredient in the press release was the size of the deal in terms of number of shares. Investors should assume it was a fixed deal. The deal was expected to close months ago, but the sudden retracement of the stock price may have weighed down the official closing of the transaction for tax purposes. There is nothing to suggest in the press releases or the company’s communication that the deal is off. In fact if the deal was off they would have been required to issue an 8-K. They have not issued an 8-K and because they “anticipated” closing in Q1 investors need to wait for the announcement of the definitive closing. With the passage of the infrastructure bill it’s almost a given that the announcement of the deal closing will be shortly thereafter.
There are clues of activity when analyzing the last 10-Q which covered the period ended March 31, 2021. The last quarter ended with 183,753,000 common shares and 12,000,000 shares of preferred stock. The total authorized share count is 200 million shares and according to OTC markets the latest count is 197,753,333 out of 200,000,000 authorized shares. So it’s very possible that this deal got done for the 15 million shares that were increased. Given the current stock price that is close to $1.0 million in consideration for the deal. For the past 3 years the share count hasn’t moved at all until now. Dilution on SODE has historically been extremely mild. The next quarterly report is due very soon and that could be a potential catalyst as investors realize the deal may have already been consummated.
The true value of the Danliv deal lies in the licenses. All these licenses are needed to effectively bid on any of these government projects. There are surely to be small business set asides for companies the size of SODE so it’s a perfect recipe for growth. Most of Danliv’s competitors are just electricians we’re assuming, with most of the potential earnings coming from the soft costs for each facet of the project. When teamed with Social Detention, they can do the whole job from start to finish including construction, assembly, permitting and not just the electrical segment of the project.
“Danliv Inc. provides us the vehicle to obtain and perform EV, Hydrogen and Green Infrastructure Projects not only in California but on a national level as well. This marks an important step forward for Social Detention Inc. and opens up opportunities for growth and revenue recognition.” – Robert P. Legg II, CEO Social Detention, Inc.
California’s Goal to Have All Electric Vehicles by 2035
President Biden announced an executive order last week that aims to make half of all new vehicles sold electric by 2030. The move is part of Biden’s larger plan for taking action on the climate crisis and has the backing of U.S. automakers. Not a legally binding mandate and more of a voluntary pledge, it remains to be seen how much progress will ultimately be made in helping lower greenhouse gas emissions. On September 23, 2020, The Office of the Governor Gavin Newsome announced an executive order that directs the state to require that, by 2035, all new cars and passenger trucks sold in California be zero-emission vehicles. (www.gov.ca.gov)
Many Democrats urged Biden to pursue a similar order, which is closer to those adopted by other countries, but he resisted. We wait for further information and Biden’s executive order and what impact California’s own policies and growing electric vehicle industry will have on the national plan. What we do know is that Social Detention and Danliv Inc are well positioned to capitalize on the EV push in California and hopefully expand into additional states if not nationally.
Exposure to Bitcoin with Bitplaza Shopping App
Social Detention Inc. announced in April of 2019 it had executed a Memorandum of Understanding to acquire Bit Plaza Inc. Bitplaza was the world’s first Bitcoin dedicated shopping app on the Apple App Store and Google Play. The shopping app uses cutting edge technology which allows anyone around the world to buy physical goods with bitcoin, from the latest electronics to even groceries. Although many retail giants are now adopting the idea of accepting bitcoin as a means of payment, Bitplaza app was the first of its kind and is definitely a target for ecommerce platforms looking to grow its customer base, especially one who are crypto related. Bitplaza claims to be actively growing the global shopping platform and building new partnerships with brands that are looking to accept Bitcoin payments on the App store.
Two months later, SODE followed up with a press release stating BitPlaza was experiencing tremendous growth as their daily downloads for the app were up 200% from the previous time period. As we all know the bear market hit crypto in late 2019 and Bitcoin fell to $3500 in March of 2020 so it’s of no surprise that we have not heard anything more about the app. On an optimistic note, Bitcoin is now flirting with a $46,000 price range and the app is still downloadable on the iTunes app store. Customers can download the app or visit Bitplaza’s operated websites @ www.bitplazashopping.com & www.bitcoinpike.com
Investment Summary
For the time being investors should consider Social Detention as an infrastructure play. It seems pretty clear that the deal with Danliv has closed and they simply are going to recognize it in the next 10-Q or wait until final passage of the infrastructure plan by congress. The company seems to be prepared to launch a bidding campaign once passage is final. California is pushing the electric car agenda pretty hard which means charging stations and the grid have to be built out ahead of time. This could be low hanging fruit for Danliv as they await the Request for Quotations from the government which will almost certainly include the construction of charging stations. The company currently has a $15 million market cap and just one of these infrastructure projects could be a game changer for the company. There is a good risk to reward ratio with an operating company that has no potential for dilution and considerable upside should they secure any infrastructure project.
Disclosure: we hold no position in SODE either long or short and we have not been compensated for this article.
Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.
The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.
To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
$ENVB halted up
— Antonio Costa (@ACInvestorBlog) May 18, 2023
Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.
$ENVB 💰💰💰💰💰 pic.twitter.com/qCIxiCpF0E
— FonsieTrader (@FonsieTrader) May 18, 2023
Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.
$ENVB 👇this is an important milestone for the company! The price could increase fivefold wit the time imo.
Enveric Biosciences Receives Notice Of Allowance From US Patent And Trademark Office For Novel Prodrug Of Psilocin
— Swingy John (@daytrader_2020) May 18, 2023
We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Image by Gino Crescoli from Pixabay
TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million.
Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities
Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) today announced a multi-year collaboration that will use TScan’s proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn’s disease.
All things considered, this is among one of the largest deals you’ll see for a micro-cap biopharma company. As many of you know, companies in this sector of this size and scale are typically not profitable – mainly focusing on R&D until their drug or technology is fully approved/commercially viable.
The critical thing to note with this deal between TScan and Amgen is that the cash milestones ensure a cash runway for TCRX, potentially even until they become commercially viable and profitable.
Here’s a breakdown of the press release in layman’s terms, so anyone without background or knowledge in this space can better understand:
Amgen and TScan Therapeutics are teaming up to find new treatments for Crohn’s disease, a chronic condition that causes inflammation in the gut. TScan has a unique platform called TargetScan that can identify the proteins recognized by the immune system in people with the disease. Amgen will use this information to create new drugs to treat Crohn’s disease.
As part of the deal, TScan will get an upfront payment of $30 million from Amgen and could earn more than $500 million if the collaboration is successful. Amgen will have the rights to develop and sell any new drugs from this partnership.
To Discover the Inside Scoop on TCRX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Both companies will be responsible for their research costs, and Amgen can expand the collaboration to include another condition called ulcerative colitis. This partnership could lead to new and better treatments for people with Crohn’s disease, who currently have limited options for managing their symptoms.
Here are a couple of blurbs from the management team:
“Anti-inflammatory drugs have traditionally been the standard of care for patients suffering from inflammatory bowel disease, but often lack efficacy and durability,” said Raymond Deshaies, Ph.D., senior vice president of Global Research at Amgen. “TScan’s platform provides a best-in-class approach to identify non-conventional drug targets to enable the development of potential first-in-class therapeutics to address unmet medical needs.”
“We’re excited to apply our target discovery platform to the autoimmunity space,” said Gavin MacBeath, Ph.D., acting chief executive officer and chief scientific and operating officer at TScan. “Our TargetScan platform, which we have now extended to identify MHC class II targets of CD4+ T cells, is well-suited for the discovery of antigens targeted by the immune system in inflammatory bowel disease. We look forward to developing the value of our platform both in this partnership with Amgen and in other autoimmune diseases.”
What’s retail saying?
As per usual, with gains of around 135%, you can probably guess that retail is all over it. Investors practically all over the internet keep their eye on the stock for potential entry points utilizing various day trading techniques.
Interestingly, some traders are surprised it managed to trade such massive volumes early intraday. If you look at their chart from the prior months, the average volume was relatively minuscule – sometimes trading as low as 5K shares a day. Compared to the ~27M shares traded at the time of writing, that’s a massive shift.
$TCRX #TCRX nice wake up call watch the break above 5.47 to potential 6.25 test pic.twitter.com/FvoAYEFslG
— APFK_ASIAN PICASSO. (@FLiPTek81) May 9, 2023
$TCRX deserves 1000% 30m upfront 500m contract!
— SHANA (@shanazaman) May 9, 2023
$TCRX ✅✅great earnings 75%gain for me
— Ethio-TradE (@alemcharity) May 9, 2023
$TCRX guess they're not done screwing with people yet. That thing looked dead next thing you know, BAM!
— madaz (@madaznfootballr) May 9, 2023
$LCID massive buyers check orderflow. Count the +ve delta numbers and check sizes. $PLTR $MOBQ $IDEX $CLRO $PYPL $TSLA $FFIE $AMD $TCRX $SOXL $SQQQ $TQQQ $NVAX $PLUG $ENSC $BOIL $XELA $NKLA $CVNA $AAPL pic.twitter.com/d0RaG1xvQl
— Time Traveler Carlssin's Trades (@StockMarketMcro) May 9, 2023
We will update you on TCRX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with TCRX.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Image by Gerd Altmann from Pixabay
On April 27, 2023, shares of ContraFect Corp (NASDAQ: CFRX) skyrocketed by 125% in pre-market trading, which is quite unusual. Although the surge may be linked to the news from the previous day, it is difficult to determine as there was not much movement on April 26.
However, sometimes it only takes the right attention from investors to create such positive rallies. It is worth noting that $CFRX has a low float of 1.53M, which can lead to extreme volatility and provide retail traders an opportunity to make significant gains.
To Find out the inside Scoop on CFRX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Summary of latest PR on April 26, 2023
ContraFect Corporation is a clinical-stage biotechnology company developing new treatments for antibiotic-resistant infections. They recently announced that they initiated a Phase 1b/2 study to test the safety, drug disposition, and efficacy of their drug candidate, Exebacase, in patients with chronic prosthetic joint infections (PJI) of the knee. The study is in France and is randomized, double-blind, and placebo-controlled, meaning some patients will receive the drug, while others will receive a placebo. The study will have two parts: Part I will evaluate the drug’s efficacy, safety, and pharmacokinetics at an early six-week time point, while Part II will assess the long-term clinical safety and efficacy of the drug for up to two years. The CEO of ContraFect Corporation is optimistic about the potential of Exebacase to replace the current surgical treatment for chronic PJI, which has not shown significant improvement in clinical outcomes in recent decades.
What are retail traders saying?
https://twitter.com/RealWillTopol/status/1651553835801001986?s=20
$CFRX
Running in Pre Market Almost +100% From PDC— Avid Trader (@RealAvidTrader) April 27, 2023
$CFRX Why LONG? 🔍👁
Premarket long pattern from the system in room
– dilution above $4
– key level $4
– shorts trapped this early morning
– pullback on trend following
– microfloat + high volumeLive Trading Alerts & Screenshare at https://t.co/ooLvigTt4P #smallcaps… pic.twitter.com/dLX0ZhUwa7
— JTrader (@jtraderco) April 27, 2023
$CFRX $2.12 $2.18 $2.25 if the next low is higher we’re in a good spot!!! https://t.co/axr4eAWTnw pic.twitter.com/k35XYJqQHI
— BULLISHWIRE (@BULLISHWIRE) April 27, 2023
It is worth noting that there has been some speculation about the events that have unfolded and the underlying factors that have led to them.
We’ve observed a subset of traders that capitalize on the volatility by adopting a watchful approach towards stocks, including $CFRX, to generate quick profits.
However, it is essential to exercise caution when considering following their lead, given the high risk associated with their investment strategies and the prevailing market conditions. While we do not typically recommend emulating their investment decisions, it may be an intriguing endeavor for those willing to assume a certain level of financial risk with funds they can afford to lose.
About ContraFect Corp (NASDAQ: CFRX)
ContraFect is a company that focuses on finding new ways to treat life-threatening infections resistant to antibiotics. Antibiotic-resistant infections are responsible for an estimated 700,000 deaths each year worldwide. ContraFect is developing new medical treatments called DLAs that include lysins and amurin peptides. Lysins are antimicrobial proteins that can quickly kill target bacteria, including those in biofilms, and can work with traditional antibiotics. Amurin peptides can fight many antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species. ContraFect believes that lysins and amurin peptides will effectively fight antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections. The company has completed a Phase 2 clinical trial for their lead lysin candidate, exebacase, designated by the FDA as a Breakthrough Therapy for treating MRSA bloodstream infections, including right-sided endocarditis, when combined with traditional antibiotics.
We will update you on CFRX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with CFRX.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Image by Sasin Tipchai from Pixabay
Wearable Devices Ltd. (NASDAQ: WLDS) Breaking Boundaries with AI
CohBar Inc. (NASDAQ: CWBR) and Morphogenesis Join Hands to Create TuHURA Biosciences
Aemetis Inc. (NASDAQ: AMTX) Pioneers Renewable Fuel Market with EPA Approval
Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment
Immutep Limited (NASDAQ: IMMP) Immuno-oncology Breakthrough with Phase 2 Trial Combining Merck & Co’s Keytruda
-
Uncategorized6 months agoMeta Materials Inc (OTCMKTS: MMTLP) Enormous Short Position in Trouble as Next Bridge Hydrocarbons Set to Stop Trading (George Palikaras & John Brda on Corporate Action)
-
Micro Cap Insider2 years agoMedium (KOK PLAY) The Parabolic Rise of Metal Arts (OTCMKTS: MTRT)
-
Media & Technology2 years agoHealthier Choices Management Corp. (OTCMKTS: HCMC) Powerful Comeback Brewing as PMI Patent Infringement Lawsuit Moves Forward
-
Media & Technology2 years ago
AMECA Mining RM; the Rise of Southcorp Capital, Inc. (OTCMKTS: STHC)
-
Media & Technology2 years agoSNPW (Sun Pacific Holding Corp) Power Brewing: 50MW solar farm project in Durango Mexico MOU with Atlas Medrecycler 48,000 SF New Partnership Queensland Australia Solar Farm.
-
BioPharma1 year agoAsia Broadband (OTCMKTS: AABB) On the Move Northbound Since Sub $0.08 Dip as Crypto Innovator Elevates AABB Crypto Exchange & Enters the NFT Space
-
Uncategorized7 months agoMeta Materials Inc (OTCMKTS: MMTLP) Short Squeeze S-1a4 Filing Signals S1 Approval Could Be Days Away (Next Bridge Hydrocarbons Spin-Off)
-
BioPharma2 years agoHumbl Inc (OTCMKTS: HMBL) Major Reversal as Powerful Advisor Rejoins the Team & Looks to Uplist to Major Exchange
